Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $8.1800 (0.25%) ($8.0400 - $8.2700) on Thu. Oct. 17, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.83% (three month average) | RSI | 52 | Latest Price | $8.1800(0.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.415% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-14%) TIP(-1%) UNG(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.415% (StdDev 2.83%) | Hourly BBV | 0 () | Intraday Trend | -0.7% | | | |
|
5 Day Moving Average | $8.08(1.24%) | 10 Day Moving Average | $7.88(3.81%) | 20 Day Moving Average | $8.18(0%) | To recent high | -38.3% | To recent low | 9.4% | Market Cap | $2.112b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |